Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27878089 | 0.80 | CYP19A1 (0.53) | CYP19A1KIF11CYP3A4LMNACYP1A2 | |
| SCHEMBL19706108 | 0.80 | CYP19A1 (0.46) | CYP19A1KIF11CYP3A4LMNACYP1A2 | |
| SCHEMBL2084239 | 0.78 | CYP19A1 (0.51) | CYP19A1KIF11CYP3A4LMNACYP1A2 | |
| SCHEMBL2082074 | 0.78 | CYP19A1 (0.77) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL19440649 | 0.76 | CYP19A1 (0.43) | CYP19A1TDP1 | |
| SCHEMBL23416769 | 0.75 | CYP3A4 (0.43) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL9165183 | 0.74 | CYP3A4 (0.58) | CYP19A1KIF11CYP3A4LMNACYP1A2 | |
| SCHEMBL19440389 | 0.74 | CYP19A1 (0.44) | CYP19A1CYP3A4KCNA5CYP3A5 | |
| SCHEMBL74389 | 0.73 | KIF11 (0.61) | CYP19A1KIF11CYP3A4LMNACYP1A2 | |
| SCHEMBL31411120 | 0.73 | TSHR (0.46) | KIF11LMNACYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CYP19A1 1569/4885KIF11 2648/4885CYP3A4 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.